1,131 results on '"ATOPIC dermatitis"'
Search Results
2. Clinical Characteristics and Therapeutic Management of Atopic Dermatitis in Elderly Patients Compared with Young Adult Patients: A Prospective Multicentre Study
- Author
-
Clément Pollyn-Millot, François Maccari, Jean Luc Perrot, Ziad Reguiai, Claire Boulard, Pierre André Becherel, Claire Poreaux, Laure Mery-Bossard, Domitille Beaulieu, Diane Pourchot, Anne-Claire Fougerousse, Edouard Begon, Anne-Laure Liegeon, Charlotte Fite, Inès Zaraa, Dominique Lons-Danic, Beatrice Walls, Caroline Jacobzone, Charlotte Lepelley, Daphné Denis, and Guillaume Chaby
- Subjects
Prevalence ,Registries ,Aged ,Atopic Dermatitis ,Observational Study ,Dermatology ,RL1-803 - Abstract
Atopic dermatitis (AD) is the most common chronic inflammatory dermatitis in developed countries, and has a major impact on those affected. Little is known about AD in elderly patients. This prospective multicentre observational study described the clinical characteristics and burden of AD in elderly subjects ≥ 65 years, as well as the therapeutic options chosen for this population in routine care, and compared findings with those in young adults with AD
- Published
- 2024
- Full Text
- View/download PDF
3. Cardio-facio-cutaneous Syndrome with Severe Inflammatory Cutaneous Lesions: Dramatic Effect of Dupilumab
- Author
-
Sara A. Altandi, Pol A. Apoil, Juliette Mazereeuw-Hautier, and Maella Severino-Freire
- Subjects
Dupilumab ,ichthyosis ,IgE ,allergy ,atopic dermatitis ,cardiofaciocutaneous syndrome ,Dermatology ,RL1-803 - Abstract
Abstract is missing (Short communication)
- Published
- 2024
- Full Text
- View/download PDF
4. Bullous Pemphigoid that Developed During Nemolizumab Treatment for Atopic Dermatitis: Two Case Reports
- Author
-
Michie Katsuta, Ryoichi Kamide, Yozo Ishiuji, Yoshimasa Nobeyama, and Akihiko Asahina
- Subjects
nemolizumab ,atopic dermatitis ,bullous pemphigoid ,itch ,IL-31 ,Dermatology ,RL1-803 - Abstract
Abstract is missing (Short communication)
- Published
- 2024
- Full Text
- View/download PDF
5. The Circadian Rhythm of Itching among 241 Adults with Atopic Dermatitis: A Cross-sectional Study
- Author
-
Xiaoxue Sang, Jianyun Lu, Lina Tan, Jinrong Zeng, Dan Wang, Aiyuan Guo, Siyuan Tang, Qian Zeng, Wei Liu, and Lihua Gao
- Subjects
atopic dermatitis ,circadian rhythm ,itch ,questionnaire ,Dermatology ,RL1-803 - Abstract
The pattern of itching in patients with atopic dermatitis has not been systematically studied. Therefore, this study aimed to assess the pattern of itching in adults with atopic dermatitis using questionnaires to assess for a circadian rhythm of itching in participating patients at a single institution (n = 241). A self-report questionnaire was used to assess circadian rhythm and intensity of itching in patients. In addition, the patients’ disease severity (Eczema Area and Severity Index [EASI]) and quality of life (Dermatology Life Quality Index [DLQI]) were assessed. Itching occurred most frequently (74.69%) and with the greatest severity (62.66%) between 20:00 and 00:00, and the least number of patients (25.31%) experienced itching between 04:00 and 08:00. The DLQI and EASI scores both correlated with the average and maximum itch intensity (r = 0.582, r = 0.533, respectively; r = 0.539, r = 0.517, respectively; p
- Published
- 2024
- Full Text
- View/download PDF
6. Cross-Cultural Validation of the RECAP of Atopic Eczema Questionnaire in a Swedish Population
- Author
-
Gunnthorunn Sigurdardottir, Mikael Alsterholm, Chris D. Andersson, Maria Bradley, MariHelen Sandström Falk, Emma K. Johansson, Maria Lundqvist, Andreas Sonesson, Åke Svensson, Grigorios Theodosiou, Sophie Vrang, and Laura B. von Kobyletzki
- Subjects
atopic dermatitis ,eczema ,patient-reported outcome measure ,validation study ,Dermatology ,RL1-803 - Abstract
A Swedish translation of the patient-reported outcome measure for assessing long-term control of atopic dermatitis, Recap of atopic eczema (RECAP), has not been validated. Cross-cultural translation and multi-centre validation of the translated RECAP questionnaire were therefore performed. Disease severity was assessed using the validated Investigator Global Assessment Scale for atopic dermatitis (vIGA-ADTM). The Swedish RECAP was completed by 208 individuals aged 16 years or older with a median age of 36 years (interquartile range [IQR] 27–48). The participants considered the questionnaire suitable for assessing eczema control. The median RECAP score (range 0–28) was 12 (IQR 5–19). The mean and median vIGA-ADTM scores (range 0–4) were 2 (standard deviation [SD] 2) and 3 (IQR 2–4), respectively. A correlation between RECAP and the vIGA-ADTM was observed (p
- Published
- 2024
- Full Text
- View/download PDF
7. Short-term Heat Application Reduces Itch Intensity in Atopic Dermatitis: Insights from Mechanical Induction and Real-life Episodes
- Author
-
Joachim W. Fluhr, Leonie Herzog, Razvigor Darlenski, Tim Mentel, and Torsten Zuberbier
- Subjects
pruritus ,epidermal barrier function ,heat ,atopic dermatitis ,Dermatology ,RL1-803 - Abstract
Heat application is known to activate transient receptor potential (TRP) channels, which play a crucial role in sensory perception, including itch. In this study, the effect of a 5-s, 49°C heat application on itch intensity in atopic dermatitis (AD) patients was evaluated. The study comprised 2 parts: a controlled trial investigating the impact of brief heat treatment on mechanically induced itch, and a real-life study of AD patients experiencing itch attacks. A significant and immediate reduction in itch sensations following heat application was shown, with effects enduring over time. This response, however, showed notable individual variability, underscoring the potential of personalized approaches in AD treatment. Repeated applications of heat showed no habituation effect, suggesting its viability as a non-pharmacological, patient-tailored option for managing itch in AD. Further research in larger cohorts is warranted to refine treatment protocols and deepen understanding of the mechanisms involved.
- Published
- 2024
- Full Text
- View/download PDF
8. Superantigen Encoding Genes in Staphylococcus aureus Isolated from Lesional Skin, Non-Lesional Skin, and Nares of Patients with Atopic Dermatitis
- Author
-
Natalia Ratusznik, Sofie Marie Edslev, Marc Stegger, and Bo Söderquist
- Subjects
Atopic Dermatitis ,Staphylococcus aureus ,Superantigens ,Enterotoxins ,TSST-1 ,Dermatology ,RL1-803 - Abstract
Patients with atopic dermatitis (AD) are more likely than healthy individuals to harbour Staphylococcus aureus on their skin. Superantigens (SAgs) produced by specific S. aureus strains may contribute to AD-associated skin inflammation. The present study compared the prevalence and types of SAg-encoding genes between S. aureus isolated from patients with AD and from controls, and within the AD group between isolates from different sampling sites (lesional skin, non-lesional skin, and nares). This retrospective case-control study extracted data from 2 previous studies that examined S. aureus using whole-genome sequencing. The 138 S. aureus isolates obtained from 71 AD patients contained 349 SAg-encoding genes; 22 (6.3%) were found in isolates from nares (0.4 ± 0.6 genes per isolate), 99 (28.4%) in isolates from non-lesional skin (3.7 ± 3.9), and 228 (65.3%) in isolates from lesional skin (4.2 ± 4.5). S. aureus (n = 101) from the control group contained 594 SAg-encoding genes (5.9 ± 4.2). Of the S. aureus isolated from lesional AD skin, 69% carried at least 1 gene encoding SAg compared with 33% of AD nasal isolates. SAg could be a factor in the pathogenesis of a subset of AD patients.
- Published
- 2024
- Full Text
- View/download PDF
9. The Impact of Atopic Dermatitis on Sexual Function and Reproductive Desires in Women
- Author
-
Juan-Angel Rodríguez-Pozo, Trinidad Montero-Vílchez, Pablo Diaz Calvillo, Raquel Sanabria de la Torre, Clara Ureña Paniego, Arena Ramirez-Muñoz, and Salvador Arias Santiago
- Subjects
Atopic Dermatitis ,Sexual Function ,Reproductive Desire ,Quality of Life ,Dermatology ,RL1-803 - Abstract
Atopic dermatitis is a prevalent skin condition that affects up to 17% of adult population. It can lead to itching, pain, and other symptoms such as sleep disturbance, anxiety, and depression. Due to its high prevalence and limiting symptoms, atopic dermatitis often has a great impact on patients’ quality of life but there is scarce information regarding how atopic dermatitis affects women’s sexual health and reproductive desires. The purpose of this article was to assess the impact of atopic dermatitis on sexual function and reproductive wishes in women. A cross-sectional study was conducted from February to March 2022. A total of 102 women with atopic dermatitis were recruited through online questionnaires sent through the Spanish Atopic Dermatitis Association; 68.6% of the patients acknowledged impairment in sexual function, especially those with more severe disease and those with genital and gluteal involvement. In addition, 51% of the women considered that atopic dermatitis may have an influence on their gestational desire, particularly those with gluteal involvement. In conclusion, atopic dermatitis has a great impact on sexual function and reproductive desires in women.
- Published
- 2024
- Full Text
- View/download PDF
10. Referral Pathways for Children with Atopic Diseases in Denmark
- Author
-
Gitte Færk, Malin Glindvad Ahlström, Viktoria Helt-Eggers Lura, Susanne Reventlow, Jeanne Duus Johansen, Jacob P. Thyssen, Kirsten Skamstrup Hansen, and Lone Skov
- Subjects
Allergic rhinitis ,Asthma ,Atopic dermatitis ,Disease management ,Food hypersensitivity ,Referral ,Dermatology ,RL1-803 - Abstract
Atopic diseases such as atopic dermatitis, food allergy, allergic rhinoconjunctivitis, and/or asthma are common. In Denmark, however, there are multiple referral pathways for these diseases in the healthcare system and they are poorly understood. To describe how children with atopic diseases navigate their way through the Danish healthcare system, a questionnaire was distributed to children aged ≤ 17 years, who were being treated for atopic diseases between August 2020 and June 2021, either by a practising specialist or a hospital department, in the Capital Region of Denmark. A total of 279 children completed the questionnaire and most were referred to a specialist or to a hospital by their general practitioner. No “common track” to hospital existed for patients with ≥ 3 atopic diseases. These patients were more often referred to a hospital compared with children with 2 atopic diseases or fewer (odds ratio [OR] 3.79; 95% CI 2.07–7.24). The primary determinants for hospital treatment were food allergy (OR 4.69; 95% CI 2.07–10.61) and asthma (OR 2.58; 95% CI 1.18–5.63). In conclusion, children with multiple atopic diseases were more likely to be referred to hospital departments than to practising specialists, mainly due to food allergies.
- Published
- 2024
- Full Text
- View/download PDF
11. Is Telemedicine Suitable for Patients with Chronic Inflammatory Skin Conditions? A Systematic Review
- Author
-
Wynanda A. van Enst, Ying Chao Weng, Sophie A. C. Wanten, Marieke M.B. Seyger, Ewout M. Baerveldt, Bernd W.M. Arents, Elke M.G.J. de Jong, and Juul M.P.A. van den Reek
- Subjects
telemedicine ,chronic inflammatory skin conditions ,remote healthcare ,atopic dermatitis ,psoriasis ,patient-friendly care ,Dermatology ,RL1-803 - Abstract
Telemedicine, the provision of remote healthcare, has gained prominence, accelerated by the COVID-19 pandemic. It has the potential to replace routine in-person follow-up visits for patients with chronic inflammatory skin conditions. However, it remains unclear whether telemedicine can effectively substitute in-person consultations for this patient group. This systematic review assessed the effectiveness and safety of telemedicine compared with traditional in-person care for chronic inflammatory skin diseases. A comprehensive search in various databases identified 11 articles, including 5 randomized controlled trials (RCTs) and 1 clinical controlled trial (CCT). These studies evaluated telemedicine’s impact on patients with psoriasis and atopic dermatitis, with varying methods like video consultations and digital platforms. The findings tentatively suggest that telemedicine does not seem to be inferior compared with in-person care, particularly in terms of condition severity and quality of life for patients with chronic inflammatory skin diseases. However, these results should be interpreted with caution due to the inherent uncertainties in the evidence. There are indications that telemedicine can offer benefits such as cost-effectiveness, time savings, and reduced travel distances, but it is important to recognize these findings as preliminary, necessitating further validation through more extensive research.
- Published
- 2024
- Full Text
- View/download PDF
12. Impact of Atopic Dermatitis on Adult Women’s Lives: A Survey of 1,009 French Women
- Author
-
Anne Claire Fougerousse, Marina Alexandre, Anne Sophie Darrigade, Stéphanie Merhand, Adrien Marquié, Medhi Hamza, Gaelle Le Fur, Marie Jachiet, Anne Claire Bursztejn, and Charles Taieb
- Subjects
atopic dermatitis ,women ,Quality of Life ,sleep ,Dermatology ,RL1-803 - Abstract
Atopic dermatitis (AD) is one of the most common inflammatory diseases, and has a higher prevalence among females in adulthood. The aim of this observational, cross-sectional, survey-based study was to evaluate the impact of AD on the daily lives of adult women patients. A scientific committee composed exclusively of women constructed a specific questionnaire in partnership with the French Eczema Association. Severity of AD was evaluated with the Patient-Oriented Eczema Measure (POEM). A sample of 1,009 adult women (mean age ± standard deviation: 41.8 ± 14.2 years) with AD was identified from a representative sample of the French population (82% response rate 1,230 women surveyed). According to the POEM, 50.64% (n = 511) of subjects were identified as having mild AD, 39.35% (n = 397) moderate AD, and 10.01% (n = 101) severe AD. Overall, 67.7% (n = 682) reported that their eczema involved a visible area (face, neck or hands), and 19.6% (n = 198) a sensual area (breasts/chest, genital area or buttocks). Of the 720 women with menstrual cycles, exacerbations of AD were reported to occur mostly before (50.6%) and during (48.3%) menstruation. A small proportion of women, 7.3% (n = 74), reported being afraid of becoming pregnant because of their eczema. If AD involvement was in a visible area it had a greater impact on romantic relationships, sexual relationships and occupation. If AD involvement was in a sensual area it had a greater influence on romantic relationships and sexuality. Particular attention should be given to patients with localization of AD on the face, neck or hands, as they have a higher risk of social exclusion. Moreover, these results should encourage health professionals to ask patients with AD about the possible involvement of sensual areas.
- Published
- 2024
- Full Text
- View/download PDF
13. Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib
- Author
-
Shawn G. Kwatra, Marjolein de Bruin-Weller, Jonathan I. Silverberg, Peter Lio, Mette Deleuran, Handan Aydin, Brian M. Calimlim, Michael C. Lane, Yingyi Liu, Sarah Ofori, and Stephan Weidinger
- Subjects
atopic dermatitis ,itch ,Janus kinase inhibitor ,skin clearance ,treat-to-target ,upadacitinib ,Dermatology ,RL1-803 - Abstract
A treat-to-target approach was recently developed to guide systemic treatment for adults with atopic dermatitis (AD). Recommendations outlined criteria for a 3-month initial acceptable treatment target and a 6-month optimal target, evaluated using global assessment of patient-reported disease severity, as well as Eczema Area and Severity Index, itch assessed on an 11-point numerical rating scale, Dermatology Life Quality Index, or Patient-Oriented Eczema Measure. Achievement of these targets with once-daily upadacitinib (15 mg and 30 mg) monotherapy was evaluated using integrated adult data from the Measure Up 1 and 2 phase 3 studies. Among the 852 patients treated with upadacitinib 15 mg or 30 mg, the 3-month initial acceptable target was achieved by >80%, >78%, and ≥87% of patients, and the 6-month optimal target was achieved by ≥53%, >61%, and >73% of patients at weeks 2, 16, and 52, respectively. Achievement of all 6 individual criteria for each of the target goals also increased over time. These findings suggest that upadacitinib 15 mg and 30 mg may help improve standards of care in patients with moderate-to-severe AD by achieving 6-month target goals at 16 weeks and as early as 2 weeks for most patients.
- Published
- 2024
- Full Text
- View/download PDF
14. Filaggrin Mutation Status and Prevention of Atopic Dermatitis with Maternal Probiotic Supplementation
- Author
-
Dinastry Pramadita Zakiudin, Jacob P. Thyssen, Claus Zachariae, Vibeke Videm, Torbjørn Øien, and Melanie Rae Simpson
- Subjects
atopic dermatitis ,child ,preschool ,filaggrin ,gene ,probiotic ,Dermatology ,RL1-803 - Abstract
The World Allergy Organization recommends probiotics in the prevention of atopic dermatitis in high-risk populations. Mutations in the filaggrin gene (FLG) result in an increased risk of atopic dermatitis through disruption of the skin keratin layer. This exploratory study investigated whether the preventive effect of maternal probiotics was evident in children with and without FLG mutations. DNA was collected from children (n = 228) from the Probiotic in the Prevention of Allergy among Children in Trondheim (ProPACT) study. Samples were analysed for 3 common FLG mutations (R501X, R2447X, and 2282del4). Overall, 7% of children had heterozygous FLG mutations; each child had only one of the 3 mutations. Mutation status had no association with atopic dermatitis (RR = 1.1; 95% CI 0.5 to 2.3). The risk ratio (RR) for having atopic dermatitis following maternal probiotics was 0.6 (95% CI 0.4 to 0.9) and RR was similar if the child expressed an FLG mutation (RR = 0.6; 95% CI 0.1 to 4.1) or wildtype FLG (RR = 0.6; 95% CI 0.4 to 0.9). The preventive effect of probiotics for atopic dermatitis was also evident in children without FLG mutation. Larger confirmatory studies are needed.
- Published
- 2024
- Full Text
- View/download PDF
15. Does Molluscum Contagiosum Need to be Managed Differently in Atopic Children?
- Author
-
Nicolas Andre, Adva Alyagon, Eman Jurban, Khen Moscovici, and Amir Horev
- Subjects
Atopic Dermatitis ,Molluscum Contagiosum ,Pediatric Dermatology ,Dermatology ,RL1-803 - Abstract
The association between molluscum contagiosum and concomitant atopic dermatitis and its impact on clinical features and treatment outcomes remains unclear. This retrospective study, conducted in the paediatric dermatology clinic of a tertiary medical centre, aimed to compare molluscum patients with and without atopic dermatitis. A total of 615 children with molluscum were included, 13.17% of whom had atopic dermatitis. While the latter group exhibited higher lesion count and itchiness (p=0.026 and p=0.044, respectively), no significant differences were observed in average lesion diameter, ulceration, purulence, and erythema (p=0.239, p=0.730, p=0.682, and p=0.296, respectively). Both groups showed comparable responses to molluscum-specific and supportive treatments, with no distinct difference in outcomes or recurrence of visits. It was concluded that atopic dermatitis does not exacerbate molluscum morbidity, inflammation markers, treatment outcomes or recurrence rates.
- Published
- 2024
- Full Text
- View/download PDF
16. Effects of Psychological Stress on Spontaneous Itch and Mechanical Alloknesis of Atopic Dermatitis
- Author
-
Qiaofeng Zhao, Mitsutoshi Tominaga, Sumika Toyama, Eriko Komiya, Tomohiro Tobita, Motoki Morita, Ying Zuo, Kotaro Honda, Yayoi Kamata, and Kenji Takamori
- Subjects
atopic dermatitis ,corticosterone ,itch ,mechanical alloknesis ,psychological stress ,Dermatology ,RL1-803 - Abstract
Atopic dermatitis (AD), a chronic inflammatory skin disease, manifests as an intractable itch. Psychological stress has been suggested to play a role in the onset and worsening of AD symptoms. However, the pathophysiological relationships between psychological stressors and cutaneous manifestations remain unclear. To elucidate the mechanisms underlying the stress-related exacerbation of itch, we investigated the effects of water stress, restraint stress and repeated social defeat stress on itch-related scratching behaviour, mechanical alloknesis and dermatitis in male NC/Nga mice with AD-like symptoms induced by the repeated application of ointment containing Dermatophagoides farina body. NC/Nga mice with AD-like symptoms were subjected to water stress, restraint stress and repeated social defeat stress, and their scratching behaviour, sensitivity to mechanical stimuli (mechanical alloknesis) and severity of dermatitis were evaluated. Social defeat stress+ Dermatophagoides farina body-treated mice exposed to stress showed slower improvements in or the exacerbation of AD-like symptoms, including dermatitis and itch. In the mechanical alloknesis assay, the mechanical alloknesis scores of social defeat stress+ Dermatophagoides farina body-treated mice exposed to stress were significantly higher than those of non-exposed social defeat stress+ Dermatophagoides farina body- and social defeat stress-treated mice. These results suggest that psychological stress delays improvements in dermatitis by exacerbating itch hypersensitivity in AD.
- Published
- 2024
- Full Text
- View/download PDF
17. A Qualitative Tool to Guide in the Interpretation of the Numerical Rating Scale for Pruritus Intensity in Patients with Atopic Dermatitis
- Author
-
Ignasi Figueras, Marta Feito, Marta García-Bustinduy, Emilio Monte-Boquet, Sandra Ros, Violeta Zaragoza, África Luca de Tena, and Francisco Javier Ortiz de Frutos
- Subjects
atopic dermatitis ,atopic eczema ,pruritus ,quality of life ,rating scale ,Dermatology ,RL1-803 - Abstract
Atopic dermatitis is a cutaneous inflammatory disease characterized by intense pruritus, which is often underestimated despite its direct impact on patients’ health-related quality of life and the high burden it poses. The authors’ goal was to design a qualitative tool to guide patients and healthcare professionals in their assessment and interpretation of pruritus intensity using a numerical rating scale. The draft of this tool, henceforth “guideline”, was developed based on a systematic literature review and focus groups comprising patients and a scientific committee. This draft was validated with an independent group of patients and the final version was designed following their feedback. According to the results of the systematic review, pruritus impacts 6 health-related quality of life domains: sleep quality; emotional status; overall health-related quality of life; physical function; social/sexual activity; productivity, particularly affecting sleep quality and the emotional domain. Patients considered that physical function was the most strongly affected domain, followed by sleep quality and emotional well-being, establishing that a minimum pruritus intensity of 4 and 7 points impacts moderately and severely, respectively, on the different domains of patients’ health- related quality of life. The guideline may help patients and healthcare professionals to interpret and assess pruritus intensity using a numerical rating scale and to understand the impact of pruritus on patients’ health-related quality of life.
- Published
- 2024
- Full Text
- View/download PDF
18. Effect of Potassium Permanganate on Staphylococcal Isolates Derived from the Skin of Patients with Atopic Dermatitis
- Author
-
Sigrid Lundgren and Andreas Sonesson
- Subjects
atopic dermatitis ,Staphylococcus aureus ,Staphylococcus epidermidis ,biofilm ,bacteria ,potassium permanganate ,Dermatology ,RL1-803 - Abstract
In atopic dermatitis (AD), Staphylococcus aureus frequently colonizes lesions, leading to superinfections that can then lead to exacerbations. The presence of biofilm-producing isolates has been associated with worsening of the disease. Potassium permanganate is used as a topical treatment of infected eczema, blistering conditions, and wounds. Little is known of its effects against microbes in AD skin. The aim of this study was to explore antibacterial and antibiofilm properties of potassium permanganate against staphylococcal isolates derived from AD skin. Viable count and radial diffusion assays were used to investigate antibacterial effects of potassium permanganate against planktonic staphylococcal isolates. The antibiofilm effects were assessed using biofilm assays and scanning electron microscopy. The Staphylococcus aureus isolates were completely killed when exposed to 0.05% of potassium permanganate. In concentrations of 0.01%, potassium permanganate inhibited bacterial biofilm formation. Eradication of established staphylococcal biofilm was observed in concentrations of 1%. Electron microscopy revealed dense formations of coccoidal structures in growth control and looser formations of deformed bacteria when exposed to potassium permanganate. This suggests antibacterial and antibiofilm effects of potassium permanganate against staphylococcal isolates derived from AD skin, when tested in vitro, and a potential role in the treatment of superinfected AD skin.
- Published
- 2024
- Full Text
- View/download PDF
19. Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator’s Global Assessment: A Post Hoc Analysis of a Phase 3 Trial
- Author
-
Michael J. Cork, Benjamin Lockshin, Andreas Pinter, Zhen Chen, Brad Shumel, and Randy Prescilla
- Subjects
Atopic dermatitis ,eczema ,dupilumab ,infants ,paediatrics ,quality of life ,Dermatology ,RL1-803 - Abstract
In young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in 162 children (aged 6 months to 5 years) with moderate-to- severe AD receiving dupilumab or placebo, plus low-potency topical corticosteroids. Post hoc analyses were performed on the full analysis set (FAS) and a subset of patients with Investigator’s Global Assessment score > 1 at week 16. The primary outcome was the proportion of patients at week 16 achieving a composite endpoint encompassing clinically meaningful changes in AD signs, symptoms and QoL: ≥ 50% improvement in Eczema Area and Severity Index; and/or ≥ 4-point reduction in worst scratch/itch numerical rating scale; and/or ≥ 6-point reduction in Children’s Dermatology Life Quality Index/Infants’ Dermatitis Quality of Life Index. Significantly more patients receiving dupilumab vs placebo achieved the composite endpoint in both the FAS (77.7% vs 24.6%, p
- Published
- 2024
- Full Text
- View/download PDF
20. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry
- Author
-
Esmé Kamphuis, Celeste M. Boesjes, Laura Loman, Marijke Kamsteeg, Inge Haeck, Anneke M.T. van Lynden-van Nes, Klaziena Politiek, Liana F. van der Gang, Marlies de Graaf, Marjolein S. de Bruin-Weller, and Marie L.A. Schuttelaar
- Subjects
Atopic dermatitis ,Hand eczema ,Abrocitinib ,JAK-inhibitor ,Daily practice ,Dermatology ,RL1-803 - Abstract
Limited daily practice data on the effect of abrocitinib in patients with atopic dermatitis are available. The aim of this multicentre prospective study is to evaluate the effectiveness and safety of abrocitinib in patients with atopic dermatitis treated in daily practice. In a subgroup, the effectiveness of abrocitinib on hand eczema was evaluated. A total of 103 patients from the BioDay registry were included in the study: week 4 (n = 95), week 16 (n = 61) and week 28 (n = 39). At week 28, the Eczema Area and Severity Index (EASI)-50/75/90 was achieved by 81.8%, 57.6%, and 18.2%, respectively, and the weekly average pruritus numerical rating scale ≤ 4 by 62.9%. The effectiveness of abrocitinib was not significantly different between dupilumab non-responders and dupilumab-naïve patients/responders, and between upadacitinib non-responders and upadacitinib-naïve patients/responders. Mean ± standard deviation Hand Eczema Severity Index decreased from 27.4 ± 27.7 at baseline to 7.7 ± 12.1 at week 28 (n = 31). Thirty-two patients (31.1%) discontinued treatment due to ineffectiveness (n = 17), adverse events (n = 9) or both (n = 3). The most frequently reported adverse event was nausea (n = 28). In conclusion, abrocitinib is an effective treatment for atopic dermatitis and can be effective for patients with previous inadequate response to dupilumab or upadacitinib. Furthermore, hand eczema can improve in patients treated with abrocitinib for atopic dermatitis.
- Published
- 2024
- Full Text
- View/download PDF
21. Characterization of Paediatric Prurigo Nodularis: A Multicentre Retrospective, Observational Study
- Author
-
Rotem Kyvayko, Tahel Fachler-Sharp, Shoshana Greenberger, Amir Horev, and Vered Molho-Pessach
- Subjects
Prurigo nodularis ,atopic dermatitis ,children ,Dermatology ,RL1-803 - Abstract
Abstract is missing (Short communication)
- Published
- 2024
- Full Text
- View/download PDF
22. Risk Factors that Impact Treatment with Oral Janus Kinase Inhibitors Among Adult Patients with Atopic Dermatitis: A Nationwide Registry Study
- Author
-
Ida Vittrup, David Thein, Simon Francis Thomsen, Alexander Egeberg, and Jacob P. Thyssen
- Subjects
Atopic dermatitis ,cardiovascular ,JAK inhibitor ,malignancy ,prevalence ,risk factor ,Dermatology ,RL1-803 - Abstract
The European Medicines Agency recently limited the use of oral Janus kinase inhibitors in certain patient populations, including those with atopic dermatitis. This cross-sectional study used the Danish national registers and Danish Skin Cohort to assess the prevalence of risk factors that potentially impact choice of treatment with oral Janus kinase inhibitors in adult patients with atopic dermatitis. From the Danish national registers and Danish Skin Cohort, 18,618 and 3,573 adults with atopic dermatitis, respectively, were identified. Half of the patients (49.5%) had, at some point, been registered to have at least 1 risk factor that could impact treatment with oral Janus kinase inhibitors. Non-modifiable risk factors recorded were cancer (5.6%), major adverse cardiovascular events (2.6%), venous thromboembolism (2.0%), smoking history (15.6%), and age ≥ 65 years (12.4%). Among patients ≥ 65 years of age, the mean (standard deviation) number of risk factors were 3 (1.4), and almost half of these patients had, at some point, been registered to have 1 or more non-modifiable risk factors in addition to their age. In conclusion, risk factors that may impact treatment with oral Janus kinase inhibitors were frequent in Danish adults with atopic dermatitis, especially among older individuals. Dermatologists need support and continuously updated long-term safety data when risk-evaluating patients with atopic dermatitis prior to initiation of advanced
- Published
- 2024
- Full Text
- View/download PDF
23. Atopic Dermatitis in the Elderly Population
- Author
-
Martina Maurelli, Andrea Chiricozzi, Ketty Peris, Paolo Gisondi, and Giampiero Girolomoni
- Subjects
atopic dermatitis in elderly ,atopic dermatitis ,elderly ,older patients ,treatment ,Dermatology ,RL1-803 - Abstract
Atopic dermatitis is a common inflammatory disease with a chronic and relapsing course. Although considered a childhood disease, it is now evident that atopic dermatitis is also common in adulthood and in the elderly population. Atopic dermatitis typically manifests with bilateral and symmetrical eczematous lesions on the face, trunk and skin folds. Itch is invariably present and may be very severe, markedly affecting daily life and sleep. In older adults, atopic dermatitis may have a high level of impact on quality of life, frequently burdening an already complex comorbid situation. The full assessment of disease burden (localizations, itch severity, sleep alterations, impact on quality of life, disease history, comorbidities) is crucial to identify the most appropriate treatment. In many cases, moderate-to-severe atopic dermatitis in the elderly population can be successfully and safely treated with biological agents inhibiting the interleukin-4/-13 pathway, whereas the use of Janus kinase inhibitors may pose concerns about the safety profile.
- Published
- 2023
- Full Text
- View/download PDF
24. Multiple Ulcerative Nodules on the Neck and Trunk: A Quiz
- Author
-
Yu Nishimura, Hiroyuki Goto, Junko Sowa-Osako, and Daisuke Tsuruta
- Subjects
anaplastic large cell lymphoma ,atopic dermatitis ,bexarotene ,large cell transformation ,mycosis fungoides. ,Dermatology ,RL1-803 - Abstract
Abstract is missing (Quiz)
- Published
- 2023
- Full Text
- View/download PDF
25. Botanical Extract Coacillium for Management of Paediatric Atopic Dermatitis: A Case Report
- Author
-
Philipp Spring
- Subjects
atopic dermatitis ,botanical extract ,cheilitis ,coacillium ,Dermatology ,RL1-803 - Abstract
Abstract is missing (Short communication)
- Published
- 2023
- Full Text
- View/download PDF
26. Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus
- Author
-
Jose J. Pereyra-Rodriguez, Esther S. Baldrich, Ricardo Ruiz-Villaverde, Eulalia B. Torres, Pablo de la C. Dobao, Ignasi F. Nart, Ángeles F. Menéndez, Ana Martin-Santiago, Javier M. Miquel, Juan F. Silvestre, and Jose C. Armario-Hita
- Subjects
atopic dermatitis ,IgE ,biological agents ,type 2 inflammatory diseases ,Dermatology ,RL1-803 - Abstract
Despite emerging evidence and advances in the management of atopic dermatitis there a lack of consensus regarding the diagnostic criteria, therapeutic approach, method to assess severity, and patient follow-up for this condition. An expert consensus study was conducted to provide recommendations on the management of patients with moderate-to-severe atopic dermatitis. The study used Delphi-like methodology based on a literature review, a summary of the scientific evidence, and a 2-round survey. The agreement of 60 panellists on 21 statements was evaluated. Consensus was pre-defined as ≥ 80% agreement of all respondents. In the first round 6 statements reached consensus. Unanimous consensus was achieved regarding therapeutic goals and patient satisfaction (maintained in the long term and periodic goals reassessment recommended every 3–6 months). In the second round, half of the statements reached consensus, all related to patient follow-up, treatment goals, and atopic comorbidities. The statements that did not reach consensus were related to diagnosis (biomarkers, allergy, and food testing) and starting patients on conventional systemic treatment rather than advanced treatment. The study assessed expert opinion regarding a variety of topics related to the clinical approach to patients with moderate-to-severe atopic dermatitis, in order to provide guidance on the diagnosis and management of patients with atopic dermatitis.
- Published
- 2023
- Full Text
- View/download PDF
27. Effects of Magnoliae Flos on Atopic Dermatitis-Like Inflammation Evaluated via Extracellular Signal-regulated Kinase or Signal Transducers and Activators of Transcription 1/3 Signalling Pathways
- Author
-
Tae-Young Gil, Bo-Ram Jin, Yea-Jin Park, Hye-Min Kim, and Hyo-Jin An
- Subjects
Atopic dermatitis ,Inflammation ,Magnoliae flos ,MAPK ,STATs ,Dermatology ,RL1-803 - Abstract
Atopic dermatitis is a chronic inflammatory skin disease. Skin is the largest organ and plays a pivotal role in protecting the body. Not only does the skin act as a physical barrier against the external environment, but it also has its own immune system. Atopic dermatitis is caused by prolonged excessive inflammatory responses that worsen under imbalanced cutaneous immune system skin conditions. Although the prevalence and burden of atopic dermatitis is increasing, the standard therapeutic agents remain unclear due to the complicated pathophysiology of the condition. The objective of this study is to examine the use of Magnoliae flos, the dried flower bud of Magnolia biondii or related plants. The effects and underlying mechanism of action of aqueous extract of the buds of Magnoliae flos (MF) were evaluated. Immortalized human keratinocytes (HaCaT) stimulated with tumour necrosis factor-α and interferon-γ mixture and NC/Nga mice stimulated with 2,4-dinitrochlorobenzene were used as atopic dermatitis models, in vitro and in vivo, respectively. The effects of MF were determined by measuring the suppression of pro-inflammatory signalling pathways, such as extracellular signal-regulated kinase or signal transducers and activators of transcription 1/3 and restoring skin barrier molecules. In conclusion, MF is a potential therapeutic alternative for the treatment of atopic dermatitis through repressing inflammatory pathways.
- Published
- 2023
- Full Text
- View/download PDF
28. Monitoring Sleep and Scratch Improves Quality of Life in Patients with Atopic Dermatitis
- Author
-
Ken-ichi Yasuda, Yozo Ishiuji, Toshiya Ebata, Takamasa Kogure, Eitaro Kondo, Arihito Ota, Toshihiro Ito, Koki Endoh, and Akihiko Asahina
- Subjects
atopic dermatitis ,scratching ,sleep ,quality of life ,actigraph ,Dermatology ,RL1-803 - Abstract
Atopic dermatitis itch may cause sleep disturbance and impair quality of life. For patients finding topical therapy difficult to continue, it is important to control itch and reduce scratching. This study developed algorithms to measure nocturnal sleep and scratch, using an actigraph device worn on the back of the hand, and assessed smartphone application feedback to improve adherence with therapy. In the first trial, actigraph measurements in 5 participants who wore the device were highly correlated with measurements by a sleep-monitoring device beneath the mattress. Total actigraph-measured scratching duration for each hour of sleep was highly correlated with measurements by a person rating infrared video-recording of the sleepers. In the second trial, 40 patients with atopic dermatitis were randomly allocated into an intervention group that used the actigraph and smartphone application, and a control group that did not. Both groups were instructed to use the same moisturizer. Dermatology Life Quality Index scores decreased significantly from baseline and were lower than those in the control group at week 8. It is suggested that the device and associated smartphone application reinforced therapy adherence, moisturizer use, and contributed to improved quality of life in patients with atopic dermatitis.
- Published
- 2023
- Full Text
- View/download PDF
29. Impact of Baricitinib on Patients’ Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry
- Author
-
Ziad Reguiai, Pierre André Becherel, Jean Luc Perrot, Anne Claire Fougerousse, Edouard Begon, Claire Poreaux, Claire Boulard, Guillaume Chaby, Charlotte Fite, Inès Zaraa, Dominique Lons-Danic, Anne-Laure Liegeon, Josiane Parier, Nathalie Quiles-Tsimaratos, Laurene David, and François Maccari
- Subjects
atopic dermatitis ,baricitinib ,Janus kinase inhibitors ,Quality of Life ,Registry ,Dermatology ,RL1-803 - Abstract
The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) registry was initiated to prospectively determine the long-term impairment caused by chronic inflammatory dermatoses on patients’ lives. The study included 88 patients starting baricitinib for treatment of atopic dermatitis. Clinical evaluation and patient-reported outcomes were recorded at baseline and after 6 and 12 months. After 6 months and 1 year of follow-up, 65 and 47 patients, respectively, were still being treated with baricitinib. Treatment failure was the main reason for discontinuation. Only 1 patient stopped baricitinib because of a side-effect. After 1 year of follow-up, the mean Eczema Area and Severity Index score decreased significantly from 20.7 to 6.4; the percentage of patients with severe atopic dermatitis decreased from 42.9% to 6.5% and a significant improvement in most patient-reported outcomes was noted. There was no difference in terms of efficacy whether or not patients were previously treated with dupilumab. The results remained stable after 6 and 12 months of treatment, which suggests a sustained efficacy of the treatment in patients who initially responded well.
- Published
- 2023
- Full Text
- View/download PDF
30. Hyperpigmentation in an Elderly Patient with Atopic Dermatitis: A Quiz
- Author
-
Zhe Wu, Wenqing Zhang, Chenglong Wu, Kaili Zhou, and Zhirong Yao
- Subjects
atopic dermatitis ,hyperpigmentation ,Addison’s disease ,Dermatology ,RL1-803 - Abstract
Abstract is missing (Quiz)
- Published
- 2023
- Full Text
- View/download PDF
31. Beyond Anxiety and Depression: Loneliness and Psychiatric Disorders in Adults with Atopic Dermatitis
- Author
-
Junfen Zhang, Laura Loman, Jantje M. Oldhoff, and Marie L.A. Schuttelaar
- Subjects
atopic dermatitis ,mental disorder ,loneliness ,disease severity ,epidemiology ,Dermatology ,RL1-803 - Abstract
There is a lack of knowledge concerning loneliness and psychiatric disorders other than anxiety and depression in patients with atopic dermatitis. This cross-sectional study was conducted within the Lifelines Cohort Study, in the Netherlands, by sending an atopic dermatitis questionnaire to adult participants (n = 135,950) in 2020. Psychiatric disorders were measured with a self-reported question and validated instrument (Mini International Neuropsychiatric Interview; M.I.N.I.), and loneliness was assessed with the validated 6-item De Jong Gierveld Loneliness Scale. In total, 56,896 subjects (mean age 55.8 years, 39.7% males) were included. Atopic dermatitis showed positive associations with self-reported chronic fatigue syndrome, burnout, depression, social phobia, panic disorder, attention deficit hyperactivity disorder, and eating disorder in the participants’ lifetimes. Based on the M.I.N.I., atopic dermatitis was positively associated with panic disorder and at least 1 anxiety disorder. In addition, subjects with atopic dermatitis were more likely to experience loneliness compared with those without atopic dermatitis. These associations were observed only in the moderate-to-severe, but not mild, atopic dermatitis group. This study raises awareness that a significant proportion of adults with atopic dermatitis feel lonely and are affected by several psychiatric disorders, especially those severely affected by atopic dermatitis. Further studies are required to evaluate if interdisciplinary care, such as the collaboration between dermatologists and psychiatrists, could optimize medical care for this vulnerable patient group.
- Published
- 2023
- Full Text
- View/download PDF
32. Abstracts from 13th Georg Rajka International Symposium on Atopic Dermatitis, Gdańsk, Poland August 31–September 2, 2023.
- Subjects
- *
ECZEMA , *ITCHING , *ATOPIC dermatitis , *HEALTH services administration , *MEDICAL personnel - Published
- 2023
- Full Text
- View/download PDF
33. Impact of Baricitinib on Patients’ Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry.
- Author
-
REGUIAI, Ziad, BECHEREL, Pierre André, PERROT, Jean Luc, FOUGEROUSSE, Anne Claire, BEGON, Edouard, POREAUX, Claire, BOULARD, Claire, CHABY, Guillaume, FITE, Charlotte, ZARAA, Inès, LONS-DANIC, Dominique, LIEGEON, Anne-Laure, PARIER, Josiane, QUILES-TSIMARATOS, Nathalie, DAVID, Laurene, and MACCARI, François
- Subjects
- *
ATOPIC dermatitis , *MEDICAL registries , *SKIN diseases , *BARICITINIB , *QUALITY of life - Abstract
The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) registry was initiated to prospectively determine the long-term impairment caused by chronic inflammatory dermatoses on patients’ lives. The study included 88 patients starting baricitinib for treatment of atopic dermatitis. Clinical evaluation and patient-reported outcomes were recorded at baseline and after 6 and 12 months. After 6 months and 1 year of follow-up, 65 and 47 patients, respectively, were still being treated with baricitinib. Treatment failure was the main reason for discontinuation. Only 1 patient stopped baricitinib because of a side-effect. After 1 year of follow-up, the mean Eczema Area and Severity Index score decreased significantly from 20.7 to 6.4; the percentage of patients with severe atopic dermatitis decreased from 42.9% to 6.5% and a significant improvement in most patientreported outcomes was noted. There was no difference in terms of efficacy whether or not patients were previously treated with dupilumab. The results remained stable after 6 and 12 months of treatment, which suggests a sustained efficacy of the treatment in patients who initially responded well. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus.
- Author
-
PEREYRA-RODRIGUEZ, Jose J., BALDRICH, Esther S., RUIZ-VILLAVERDE, Ricardo, TORRES, Eulalia B., DOBAO, Pablo DE LA C., NART, Ignasi F., MENÉNDEZ, Ángeles F., MARTIN-SANTIAGO, Ana, MIQUEL, Javier M., SILVESTRE, Juan F., and ARMARIO-HITA, Jose C.
- Subjects
- *
ATOPIC dermatitis , *DELPHI method , *LITERATURE reviews , *PATIENT satisfaction , *IMMUNOGLOBULIN E - Abstract
Despite emerging evidence and advances in the management of atopic dermatitis there a lack of consensus regarding the diagnostic criteria, therapeutic approach, method to assess severity, and patient follow-up for this condition. An expert consensus study was conducted to provide recommendations on the management of patients with moderate-to-severe atopic dermatitis. The study used Delphi-like methodology based on a literature review, a summary of the scientific evidence, and a 2-round survey. The agreement of 60 panellists on 21 statements was evaluated. Consensus was predefined as ≥80% agreement of all respondents. In the first round 6 statements reached consensus. Unanimous consensus was achieved regarding therapeutic goals and patient satisfaction (maintained in the long term and periodic goals reassessment recommended every 3–6 months). In the second round, half of the statements reached consensus, all related to patient follow-up, treatment goals, and atopic comorbidities. The statements that did not reach consensus were related to diagnosis (biomarkers, allergy, and food testing) and starting patients on conventional systemic treatment rather than advanced treatment. The study assessed expert opinion regarding a variety of topics related to the clinical approach to patients with moderate-to-severe atopic dermatitis, in order to provide guidance on the diagnosis and management of patients with atopic dermatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Crisaborole Inhibits Itch and Pain by Preventing Neutrophil Infiltration in a Mouse Model of Atopic Dermatitis.
- Author
-
PAVLENKO, Darya, SEVEN, Zeynep Todurga, BYSTROM, Lauren, MARKAN, Anika, VERPILE, Rebecca, ISHIDA, Hirotake, and AKIYAMA, Tasuku
- Subjects
- *
ITCHING , *ATOPIC dermatitis , *LABORATORY mice , *ANIMAL disease models , *DORSAL root ganglia , *NEUTROPHILS - Abstract
Crisaborole, a phosphodiesterase 4 (PDE4) inhibitor, has been approved for the treatment of mild to moderate atopic dermatitis. Atopic dermatitis is often associated with increased pain. Using a mouse model, this study investigated whether crisaborole suppresses pain associated with atopic dermatitis and the potential mechanisms underlying it. The mouse model for atopic dermatitis was developed by repeatedly applying MC903. MC903-treated mice had increased spontaneous scratching (itch-related behaviour) and wiping behaviour (pain-related behaviour). Crisaborole was topically applied to the cheek skin of MC903-treated mice, and it reduced both itch- and pain-related behaviours in these mice. Immunofluorescence staining revealed that crisaborole reduced neutrophil infiltration and interaction of neutrophils with sensory neurones. Intradermal injection of S100A8/A9, proinflammatory neutrophil mediator, enhanced not only itch-related behaviours evoked by histamine or chloroquine, but also pain-related behaviours evoked by capsaicin. Calcium imaging of mouse dorsal root ganglion neurones revealed that pretreatment with S100A8/A9 significantly increased calcium responses to histamine and capsaicin, and the proportion of chloroquine-sensitive neurones. These findings suggest that the PDE4 inhibitor reduces itch and pain, in part by inhibiting infiltration of S100A8/A9-containing neutrophils in a mouse model of MC903-induced atopic dermatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Atopic Dermatitis in the Elderly Population.
- Author
-
MAURELLI, Martina, CHIRICOZZI, Andrea, PERIS, Ketty, GISONDI, Paolo, and GIROLOMONI, Giampiero
- Subjects
- *
ATOPIC dermatitis , *OLDER people , *ITCHING , *DISEASE relapse , *JUVENILE diseases , *CHRONIC diseases - Abstract
Atopic dermatitis is a common inflammatory disease with a chronic and relapsing course. Although considered a childhood disease, it is now evident that atopic dermatitis is also common in adulthood and in the elderly population. Atopic dermatitis typically manifests with bilateral and symmetrical eczematous lesions on the face, trunk and skin folds. Itch is invariably present and may be very severe, markedly affecting daily life and sleep. In older adults, atopic dermatitis may have a high level of impact on quality of life, frequently burdening an already complex comorbid situation. The full assessment of disease burden (localizations, itch severity, sleep alterations, impact on quality of life, disease history, comorbidities) is crucial to identify the most appropriate treatment. In many cases, moderate-to-severe atopic dermatitis in the elderly population can be successfully and safely treated with biological agents inhibiting the interleukin-4/-13 pathway, whereas the use of Janus kinase inhibitors may pose concerns about the safety profile. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
37. Nocturnal Scratching and Quality of Sleep in Children with Atopic Dermatitis.
- Author
-
SUGIYAMA, Akiko, MURAKAMI, Yoko, OKAMOTO, Kazuaki, NAKANO, Hiroshi, WAKATSUKI, Masatoshi, KAWANO, Toshiaki, AKAMINE, Yuko, IWATA, Mihoko, MOTOMURA, Chikako, KOJIMA, Kaoru, ODA, Makiko, HONJO, Satoshi, ODAJIMA, Hiroshi, NAKAHARA, Takeshi, FURUE, Masutaka, and IKOMA, Akihiko
- Subjects
- *
SLEEP quality , *ATOPIC dermatitis , *SLEEP stages , *SLEEP disorders , *ITCHING - Abstract
Itching due to atopic dermatitis causes sleep disorders in children, but its pathology is unknown. The aim of this study is to investigate nocturnal scratching as an indirect index of itching during sleep and its relationship with depth of sleep in children with atopic dermatitis. Nocturnal scratching was measured in a total of 20 children with atopic dermatitis, using a smartwatch installed with the application Itch Tracker. Depth of sleep was analysed using polysomnography. The severity of atopic dermatitis was scored using Eczema Area and Severity Index (EASI) and Patient-Oriented Eczema Measure (POEM). The number and time of nocturnal scratching measured by Itch Tracker had a significantly positive correlation with EASI scores, whereas POEM scores were not correlated with EASI scores. Mean sleep efficiency was 90.0% and scratching episodes (n=67) started mainly during the awake stage or light sleep stages. In the scratching episodes that started during sleep stages (n=34), the sleep stage changed to a lighter one or to the awake stage in 35.5% of episodes. Itch Tracker is applicable to measure nocturnal scratching in children. Nocturnal scratching can deteriorate quality of sleep by changing the sleep stage to a lighter one or to the awake stage. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Monitoring Sleep and Scratch Improves Quality of Life in Patients with Atopic Dermatitis.
- Author
-
YASUDA, Ken-ichi, ISHIUJI, Yozo, EBATA, Toshiya, KOGURE, Takamasa, KONDO, Eitaro, OTA, Arihito, ITO, Toshihiro, ENDOH, Koki, and ASAHINA, Akihiko
- Subjects
- *
ATOPIC dermatitis , *SLEEP interruptions , *QUALITY of life , *MOBILE apps , *SLEEP , *POLYSOMNOGRAPHY - Abstract
Atopic dermatitis itch may cause sleep disturbance and impair quality of life. For patients finding topical therapy difficult to continue, it is important to control itch and reduce scratching. This study developed algorithms to measure nocturnal sleep and scratch, using an actigraph device worn on the back of the hand, and assessed smartphone application feedback to improve adherence with therapy. In the first trial, actigraph measurements in 5 participants who wore the device were highly correlated with measurements by a sleep-monitoring device beneath the mattress. Total actigraph-measured scratching duration for each hour of sleep was highly correlated with measurements by a person rating infrared video-recording of the sleepers. In the second trial, 40 patients with atopic dermatitis were randomly allocated into an intervention group that used the actigraph and smartphone application, and a control group that did not. Both groups were instructed to use the same moisturizer. Dermatology Life Quality Index scores decreased significantly from baseline and were lower than those in the control group at week 8. It is suggested that the device and associated smartphone application reinforced therapy adherence, moisturizer use, and contributed to improved quality of life in patients with atopic dermatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. Prevalence of Isotretinoin Therapy in Adolescents and Young Adults With and Without Atopic Dermatitis: A Nationwide Prescription based Population Study.
- Author
-
MOHN, Cathrine H., BLIX, Hege S., BRÆND, Anja Maria, NAFSTAD, Per, and HALVORSEN, Jon Anders
- Subjects
- *
ATOPIC dermatitis , *YOUNG adults , *ISOTRETINOIN , *TEENAGERS , *MEDICAL prescriptions - Abstract
Although isotretinoin has anti-inflammatory and immunomodulatory properties, it can exacerbate atopic dermatitis. National estimates of the extent to which patients with atopic dermatitis are affected by severe acne and isotretinoin tolerability are lacking. The aim of this study is to investigate isotretinoin therapy in patients with atopic dermatitis and to compare the nationwide prevalence with individuals without atopic dermatitis. All Norwegian residents were followed for 17 years until age 20–22 years in 2020. Approximately 28% of patients with atopic dermatitis had been treated for acne, and 8% had received isotretinoin before age 23 years. In those over 17 years old, significantly more patients with atopic dermatitis were treated with isotretinoin than those without. At age 22 years, 2.21% (95% confidence interval 1.92–2.49) of patients with atopic dermatitis were treated with isotretinoin, compared with 1.55% (95% confidence interval 1.44–1.65) of those without, representing 42.8% (1.43; 95% confidence interval 1.24–1.65) higher use in patients with atopic dermatitis. Patients who received long-term treatment (probable severe atopic dermatitis) tolerated isotretinoin similarly to patients who received short-term treatment (probable mild atopic dermatitis). There was significantly higher use of topical corticosteroids during isotretinoin therapy in patients with atopic dermatitis. Conclusively, severe acne (isotretinoin therapy) was associated with atopic dermatitis at the population level in young adults. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Narrowband-ultraviolet B vs Broadband-ultraviolet B in Treatment of Chronic Pruritus: A Randomized, Single-blinded, Non-inferiority Study.
- Author
-
KUPSA, Romana, GRUBER-WACKERNAGEL, Alexandra, HOFER, Angelika, QUEHENBERGER, Franz, WOLF, Peter, and LEGAT, Franz J.
- Subjects
- *
ITCHING , *SLEEP interruptions , *CHRONIC kidney failure , *VISUAL analog scale , *ATOPIC dermatitis - Abstract
Narrowband-ultraviolet B has shown increased efficacy over broadband-ultraviolet B in pruritic skin diseases, such as psoriasis and atopic dermatitis. In patients with chronic pruritus, e.g. in end-stage renal disease, broadband-ultraviolet B is recommended, but narrowband-ultraviolet B has also shown efficacy in reducing pruritus. This randomized, single blinded, non-inferiority study investigated the effects of narrowband-ultraviolet B compared with broadbandultraviolet B. Patients with chronic pruritus were treated with either broadband- or narrowband-UVB 3 times a week for 6 weeks and clinical response was monitored. Pruritus, sleep disturbance, and the patients’ subjective overall response to treatment were evaluated by the patients on a visual analogue scale (0–10). Skin excoriations were evaluated by investigators on a 4-point scale (0–3). Both phototherapeutic modalities showed significant antipruritic activity (itch reduction 48% and 66.4%, respectively) by broadband-ultraviolet B and narrowband-ultraviolet B. Narrowband-ultraviolet B proved to be not inferior to broadband-ultraviolet B in treating pruritus in patients with chronic pruritus, assuming a 20% noninferiority margin. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. Establishment and Utility of SwedAD: A Nationwide Swedish Registry for Patients with Atopic Dermatitis Receiving Systemic Pharmacotherapy.
- Author
-
ALSTERHOLM, Mikael, SVEDBOM, Axel, ANDERSON, Chris D., SOMMAR, Lena HOLM, IVERT, Lina U., JOSEFSON, Anna, KOBYLETZKI, Laura von, LINDBERG, Magnus, LUNDEBERG, Lena, LUNDQVIST, Maria, NYLANDER, Elisabet, FALK, MariHelen SANDSTRÖM, SHAYESTEH, Alexander, SIGURDARDOTTIR, Gunnthorunn, SONESSON, Andreas, SVENSSON, Åke, VIRTANEN, Marie, VRANG, Sophie, WAHLGREN, Carl-Fredrik, and BRADLEY, Maria
- Subjects
- *
ATOPIC dermatitis , *MEDICAL registries , *DRUG therapy , *QUALITY of life , *ECZEMA - Abstract
SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmacotherapy, was launched on 1 September 2019. We describe here the establishment of a user-friendly registry to the benefit of patients with atopic dermatitis. By 5 November 2022, 38 clinics had recorded 931 treatment episodes in 850 patients with an approximate national coverage rate of 40%. Characteristics at enrolment included median Eczema Area and Severity Index (EASI) 10.2 (interquartile range 4.0, 19.4), Patient-Oriented Eczema Measure (POEM) 18.0 (10.0, 24.0), Dermatology Life Quality Index (DLQI) 11.0 (5.0, 19.0) and Peak Itch Numerical Rating Scale-11 (NRS-11) 6.0 (3.0, 8.0). At 3 months, median EASI was 3.2 (1.0, 7.3) and POEM, DLQI, and NRS-11 were improved. Regional coverage varied, reflecting the distribution of dermatologists, the ratio of public to private healthcare, and difficulties in recruiting certain clinics. This study highlights the importance of a nationwide registry when managing systemic pharmacotherapy of atopic dermatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
42. Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
- Author
-
BOESJES, Celeste M., VAN DER GANG, Liana F., ZUITHOFF, Nicolaas P. A., BAKKER, Daphne S., SPEKHORST, Lotte S., HAECK, Inge, KAMSTEEG, Marijke, de GRAAF, Marlies, and DE BRUIN-WELLER, Marjolein S.
- Subjects
- *
ATOPIC dermatitis , *DUPILUMAB , *BARICITINIB , *ACNEIFORM eruptions , *HERPES simplex - Abstract
Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the effectiveness of 16 weeks of upadacitinib treatment for moderate-to-severe atopic dermatitis in adult patients, including those with previous inadequate response to dupilumab and/or baricitinib, in daily practice. A total of 47 patients from the Dutch BioDay registry treated with upadacitinib were included. Patients were evaluated at baseline, and after 4, 8 and 16 weeks of treatment. Effectiveness was assessed by clinician- and patient-reported outcome measurements. Safety was assessed by adverse events and laboratory assessments. Overall, the probabilities (95% confidence intervals) of achieving Eczema Area and Severity Index ≤7 and Numerical Rating Scale – pruritus ≤4 were 73.0% (53.7–86.3) and 69.4% (48.7–84.4), respectively. The effectiveness of upadacitinib was comparable in patients with inadequate response to dupilumab and/or baricitinib and in patients who were naïve for these treatments or who had stopped such treatments due to adverse events. Fourteen (29.8%) patients discontinued upadacitinib due to ineffectiveness, adverse events or both (8.5%, 14.9% and 6.4%, respectively). Most frequently reported adverse events were acneiform eruptions (n=10, 21.3%), herpes simplex (n=6, 12.8%), nausea and airway infections (both n=4, 8.5%). In conclusion, upadacitinib is an effective treatment for patients with moderate-to-severe atopic dermatitis, including those with previous inadequate response to dupilumab and/ or baricitinib treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
43. Factors Associated with Eczema Clinical Trial Awareness, Interest, and Participation in Adults.
- Author
-
GRINICH, Erin E., THIBAU, Isabelle J., LATOUR, Emile, PRICE, Kyla N., LOISELLE, Allison R., SIMPSON, Eric, and BEGOLKA, Wendy SMITH
- Subjects
- *
CLINICAL trials , *ECZEMA , *PARTICIPATION , *SUBURBS , *ADULTS - Abstract
Despite the need for improved eczema therapies and a rapid increase in available eczema clinical trials, participation remains low. The aim of this study was to identify factors associated with clinical trial awareness, interest, and barriers to enrolment and participation. An online survey, administered 1 May to 6 June 2020 to adults (≥18 years) with eczema in the USA, was analysed. Among 800 patients included, mean age was 49.4 years, most respondents were female (78.1%), White (75.4%), non-Hispanic (91.4%), and geographically living in an urban/suburban area (Rural-Urban Continuum Codes (RUCC) 1–3, 90.8%). Only 9.7% of respondents reported previous participation in clinical trials, while 57.1% had considered participation and 33.2% never considered participation. Higher satisfaction with current eczema therapy, clinical trial literacy, and confidence in finding eczema trial information were all associated with clinical trial awareness, interest, and successful participation. Younger age and having atopic dermatitis were associated with increased awareness, while female gender was a barrier to interest and successful participation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. Therapeutic Effect of Dupilumab on Systemic and Vascular Inflammation in Adults with Severe Atopic Dermatitis: Feasibility Study Using 18F-Fluorodeoxyglucose Positron Emission TomographyComputed Tomography.
- Author
-
Gi-Wook LEE, Keunyoung KIM, Seong-Jang KIM, Kihyuk SHIN, Hoonsoo KIM, Hyun-Chang KO, Moon-Bum KIM, and Byungsoo KIM
- Subjects
- *
POSITRON emission tomography , *POSITRON emission tomography computed tomography , *ATOPIC dermatitis , *DUPILUMAB , *TREATMENT effectiveness - Abstract
Atopic dermatitis (AD) is an inflammatory skin disease associated with increased systemic and vascular inflammation. Although dupilumab has been proven to be effective against severe AD, imaging studies analysing its inflammation-reducing effect have rarely been reported. The aim of this study was to evaluate the effect of dupilumab on systemic and vascular inflammation in adult patients with severe AD, using 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT). A total of 33 adult patients with severe AD and 25 healthy controls underwent 18F-FDG PET/CT at baseline. Patients on dupilumab treatment underwent 18F-FDG PET/CT again after achieving a 75% reduction from baseline on the Eczema Area and Severity Index (EASI-75). Patients with AD exhibited increased 18F-FDG uptake values in the liver, spleen, pancreas, and carotid artery compared with healthy controls. However, compared with baseline, there was no statistically significant difference in 18F-FDG uptake in major organs and arteries after achieving EASI-75 with dupilumab treatment. In conclusion, while dupilumab treatment resulted in a significant clinical improvement and reduced serum inflammatory markers in adult patients with severe AD, no changes in systemic and vascular inflammation were observed on 18F-FDG PET/CT imaging. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
45. Effects of Early Emollient Use in Children at High Risk of Atopic Dermatitis: A German Pilot Study.
- Author
-
HARDER, Inken, STÖLZL, Dora, SANDER, Nicole, HARTMANN, Jan, RODRIGUEZ, Elke, MAZUR, Carsten, KERZEL, Sebastian, KABESCH, Michael, KÜSTER, Denise, SCHMITT, Jochen, FÖLSTER-HOLST, Regina, GERDES, Sascha, EMMERT, Hila, and WEIDINGER, Stephan
- Subjects
- *
ATOPIC dermatitis , *SKIN physiology , *PILOT projects , *SKIN examination - Abstract
Several small studies have indicated that daily emollient use from birth might delay, suppress or prevent atopic dermatitis (AD). Two larger trials did not confirm this; however, a recent smaller study indicated a protective effect if daily emollient use is used in the first 2 months of life. Further research is needed to evaluate the effect of emollient use on development of AD. The current study randomly assigned 50 newborns who were at high risk of developing AD (1:1) to receive general infant skin-care advice (control group), or skin-care advice plus emollient with advice to apply emollient at least once daily until 1 year of age (intervention group). Repeated skin examinations, skin physiology measurements and skin microbiome profiling were performed. Of the children in the intervention and control groups, 28% and 24%, respectively, developed AD (adjusted Relative Risk (RR) 1.19, p=0.65, adjusted risk difference 0.05). Skin pH decreased and transepidermal water loss and stratum corneum hydration increased over time in both groups with no significant differences. In the intervention group skin microbiome alpha diversity increased earlier, and the abundance of Streptococcus and Staphylococcus species were significantly reduced at month 1. Daily early emollient use in children with high risk of AD was safe, but it did not significantly reduce the risk of developing AD or impact skin physiology development. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. The Treat-to-Target Project in Atopic Dermatitis: One Year On.
- Author
-
DE BRUIN-WELLER, Marjolein, DELEURAN, Mette, BIEDERMANN, Tilo, BISSONNETTE, Robert, FOLEY, Peter, GIROLOMONI, Giampiero, HERCOGOVÁ, Jana, HONG, Chih-Ho, KATOH, Norito, PINK, Andrew E., RICHARD, Marie-Aleth, SHUMACK, Stephen, SILVESTRE, Juan F., THYSSEN, Jacob P., and WEIDINGER, Stephan
- Subjects
- *
ATOPIC dermatitis , *CHRONIC diseases - Abstract
Atopic dermatitis is a chronic skin condition for which a range of systemic treatments have recently been approved. A treat-to-target strategy has been developed previously alongside an algorithm to guide the management of patients with atopic dermatitis. Here, we review the strategy and algorithm in the context of the evolving therapeutic landscape, and identify areas for further refinement and development. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
47. Itch and Janus Kinase Inhibitors.
- Author
-
Yujin HAN, Yu Ri WOO, Sang Hyun CHO, Jeong Deuk LEE, and Hei Sung KIM
- Subjects
- *
ITCHING , *KINASE inhibitors , *CREATINE kinase , *LICHEN planus , *ATOPIC dermatitis , *AUTOIMMUNE diseases - Abstract
Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways. Chronic itch is understood to be processed by the latter and is difficult to treat with traditional pruritus therapies. The Janus kinase and signal transducer and activator of transcription pathway is a signalling mechanism that regulates gene expression through various cytokines. Janus kinase inhibitors, which have been tested and used for several autoimmune diseases, have also been shown to be effective for itch through clinical trials and case reports. Janus kinase inhibitors could be a good choice for pruritus in atopic dermatitis, psoriasis, and other diseases, such as prurigo nodularis and lichen planus, with rapid itch relief compared with conventional treatments. The most common adverse effects reported include nasopharyngitis, acne, and elevated blood creatine phosphokinase levels. Janus kinase inhibitors are currently prescribed with warnings about a potential increase in malignancies and cardiovascular diseases and usage in people of older ages. This review aims to provide knowledge about itch and the Janus kinase and signal transducer and activator of transcription pathway and to analyse the current evidence for itch relief by Janus kinase inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. Impact of Atopic Dermatitis on Patients and their Partners.
- Author
-
MISERY, Laurent, SENESCHAL, Julien, CORGIBET, Florence, HALIOUA, Bruno, MARQUIÉ, Adrien, MERHAND, Stéphanie, LEFUR, Gaelle, STAUMONT-SALLE, Delphine, BERGQVIST, Christina, TAIEB, Charles, EZZEDINE, Khaled, and RICHARD, Marie-Aleth
- Subjects
- *
ATOPIC dermatitis , *EPWORTH Sleepiness Scale , *FRENCH people , *LUST , *INSOMNIACS , *SKIN diseases - Abstract
Atopic dermatitis is a chronic, relapsing and inflammatory skin disease. The impact of atopic dermatitis on the partners living with patients has been poorly investigated. The objective of this study was to evaluate the impact of atopic dermatitis in the daily lives of adult patients and to assess the burden of the disease on their partners. A population-based study was conducted on a representative sample of the general population of French adults aged 18 years of age using stratified, proportional sampling with a replacement design. Data were collected on 1,266 atopic dermatitis patient-partner dyads (mean age of patients 41.6 years, 723 (57.1%) women). The mean age of partners was 41.8 years. Patient burden, measured by the Atopic Dermatitis Burden Scale for Adults (ABS-A) score, was closely related to the objective atopic dermatitis severity: the mean score in the mild group (29.5) was significantly lower than in the moderate (43.9) and severe groups (48.6) (p<0.0001). Partner burden, measured by the EczemaPartner score, was highly related to atopic dermatitis severity (p<0.0001). Daytime sleepiness, measured by the Epworth Sleepiness Scale, showed a mean score of 9.24 in patients and 9.01 in their partners, indicating impaired sleep. Atopic dermatitis was found to decrease sexual desire in 39% and 26% of partners and patients respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. Happiness Behind the Scenes: Associations between Heuristic Happiness and Related Dimensions in Skin Diseases.
- Author
-
WEIS, Johanna, WECKER, Hannah, ARNOLD, Alexander, SCHUSTER, Barbara, ZIEHFREUND, Stefanie, TIZEK, Linda, MITTAG, Sonja, BIEDERMANN, Tilo, and ZINK, Alexander
- Subjects
- *
SKIN diseases , *HAPPINESS , *LIFE satisfaction , *ATOPIC dermatitis , *AFFECT (Psychology) - Abstract
Positive health approaches, such as happiness, are largely unexplored in medicine, including dermatology. Taking into consideration the various happiness measures, the aims of this cross-sectional study were to assess this concept using a 1-item heuristic happiness question and its related dimensions (Satisfaction with Life, Positive and Negative Affect, Quality of Life, and Compound Psychological Capital) in outpatients with different skin diseases between December 2019 and June 2020, and to examine the link between these dimensions. Overall, 414 dermatological patients were included: 67 with psoriasis, 84 atopic eczema, 10 mastocytosis, 19 nummular eczema, 84 malignant melanoma and 150 keratinocyte carcinoma. Comparing the skin diseases, differences were observed for heuristic happiness, Positive Affect, and some domains of Quality of Life and Compound Psychological Capital. Analysing the relationship between heuristic happiness and other happiness measures, the data revealed moderate to strong correlations (r=0.30–0.46, p<0.001) and variations in the understanding of happiness between the skin diseases. Overall, the most important facet of happiness was Hope as a domain of Compound Psychological Capital. This study emphasizes the individual definition of heuristic happiness in patients with skin diseases. A 1-item heuristic approach may be a simple and practical method to assess the complexity and individuality of happiness. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
50. Effect of Paediatric Atopic Dermatitis on Parental Sleep Quality.
- Author
-
FORER, Ester, TRIPTO, Inbal GOLAN, BARI, Romi, SHAKI, David, GOLDBART, Aviv, and HOREV, Amir
- Subjects
- *
SLEEP quality , *ATOPIC dermatitis , *SLEEP latency , *SLEEP interruptions , *SLEEP duration - Abstract
Data on the impact of paediatric atopic dermatitis on parental sleep are scarce. The aim of this study was to examine the effects of paediatric atopic dermatitis on the quality of parents’ sleep. This cross-sectional study included parents of patients with atopic dermatitis and parents of healthy children who completed validated Pittsburgh Sleep Quality Index questionnaires. The study and control groups were compared, as were results for mild and moderate atopic dermatitis with severe atopic dermatitis, mothers and fathers, and different ethnic groups. A total of 200 parents were enrolled. Sleep latency was significantly longer in the study group compared with the control group. Sleep duration was shorter in the parents of the mild AD group compared with the moderate-severe and control groups. Parents in the control group reported more daytime dysfunction than parents in the AD group. Fathers of children with AD reported more sleep disturbance than mothers. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.